Overview
QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.
Work here?Claim your company
About QuidelOrtho
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1937
Get referred to QuidelOrtho
See people who can refer or advise you
Simplify's Take
What believers are saying
- LEX launch later in 2026 adds a high-growth point-of-care molecular product.
- Ex-China revenue grew 6% constant currency in Q2 2026, showing core franchise resilience.
- Cost actions target $50 million net savings through 2027, supporting margin expansion.
What critics are saying
- China's IVD pricing guidelines crushed Q2 2026 revenue 23.3% and guide cuts persist.
- Free cash flow guidance was withdrawn after Q2 2026; deleveraging slips if China worsens.
- A $2.8 billion debt load and B+ negative outlook leave bankruptcy risk if execution fails.
What makes QuidelOrtho unique
- QuidelOrtho's LEX VELO, acquired April 2026, delivers PCR results in six minutes.
- Its immunoassay, molecular, and transfusion platforms span point-of-care through hospital laboratories.
- VITROS 450 and high-sensitivity troponin broaden a sticky installed base across care settings.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$3.4B
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Employee Assistance Program
Wellness Program
Stock Price
Growth & Insights and Company News
6 month growth
7%1 year growth
7%2 year growth
7%QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective 28 September 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research. Most recently, he served as Senior Director of Investor Relations at Teva Pharmaceuticals. He previously spent more than a decade at Genpact in investor relations and business strategy roles, and nearly six years in sell-side equity research. Sharma holds a master's degree in finance and is a Chartered Financial Analyst. QuidelOrtho is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing.
QuidelOrtho taps a 20-year IR veteran to lead shareholder communications. 7 October 2026, 11:58 AM Leadership change centers on "sharpening communications" with a newly appointed VP of Investor Relations. QuidelOrtho Corporation (NASDAQ:QDEL) announced the appointment of Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. The company said Sharma brings more than 20 years of experience spanning investor relations, corporate strategy, and equity research at global organizations. In the press release, Chief Financial Officer Micah Young highlighted Sharma's combination of investor relations leadership, healthcare experience, financial expertise, and capital markets perspective, describing it as especially valuable as QuidelOrtho works to "sharpen our communications and deepen our engagement with shareholders and analysts." Sharma's background blends healthcare IR and sell-side research experience. QuidelOrtho pointed to Sharma's most recent role as Senior Director of Investor Relations at Teva Pharmaceuticals, where he worked with senior leadership to communicate strategy and strengthen engagement with the investment community "during a period of significant transformation." Before Teva, he spent more than a decade at Genpact in progressively senior roles across investor relations and business strategy, and earlier in his career he spent nearly six years in sell-side equity research.
Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility. RARITAN, N.J. - Another longtime New Jersey business facility is heading for the exits. QuidelOrtho plans to close its 66-acre Route 202 campus in Raritan [...] |!| Raritan
QuidelOrtho Corporation has risen 31.7% over three months, but faces headwinds that may limit further gains. The diagnostics company reported second-quarter revenues of $630.9 million, up 2.8% year over year, with Labs, Immunohematology and Point of Care segments all posting growth. Excluding China, revenues grew 6% at constant currency. Adjusted EBITDA increased 21% to $129 million, reaching a 20.5% margin, supported by ongoing cost optimisation efforts targeting $50 million in net savings through 2027. However, China revenues fell 23.3% at constant currency due to distributor inventory reductions ahead of pricing changes. Management expects these challenges to persist through 2026. QuidelOrtho lowered its full-year revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and cut adjusted earnings guidance to 65-90 cents per share from $1.80-$2.00, citing China weakness and conservative respiratory season assumptions.
QuidelOrtho reported second-quarter revenues of $630.9 million, up 2.8% year-over-year and exceeding analyst expectations by 2.1%. The company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, develops diagnostic testing solutions for healthcare providers. Chief executive Brian Blaser noted strong performance across core franchises and regions, except China, where proposed IVD pricing guidelines and softer respiratory demand created headwinds. The broader healthcare equipment and supplies sector showed strength in Q2, with 36 tracked stocks beating revenue estimates by 2% on average. However, next quarter's guidance came in 1.7% below consensus. QuidelOrtho's shares fell 12.3% following its earnings announcement, which included weaker full-year guidance than peers. The stock currently trades at $14.31.
QuidelOrtho is Hiring for 30 Jobs on Simplify!
Find jobs on Simplify and start your career today
About QuidelOrtho
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1937
QuidelOrtho is Hiring for 30 Jobs on Simplify!
Find jobs on Simplify and start your career today